Full Text View
Tabular View
No Study Results Posted
Related Studies
Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.
This study is currently recruiting participants.
Verified January 2011 by University of Zurich
Study NCT01073839   Information provided by University of Zurich

First Received on June 25, 2009.   Last Updated on January 10, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cholangiocellular Carcinoma
Additional conditions recognized in this trial
Carcinoma
Cholangiocarcinoma
More general conditions related to this trial
Adenocarcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Cisplatin and Gemcitabine
Additional drug interventions recognized in this trial
Cisplatin
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
University of Zurich


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services